ELZITUDE Trademark

Trademark Overview


On Monday, May 24, 2021, a trademark application was filed for ELZITUDE with the United States Patent and Trademark Office. The USPTO has given the ELZITUDE trademark a serial number of 90729626. The federal status of this trademark filing is WITHDRAWN BEFORE PUBLICATION as of Tuesday, January 11, 2022. This trademark is owned by Bristol-Myers Squibb Company. The ELZITUDE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Phar...
elzitude

General Information


Serial Number90729626
Word MarkELZITUDE
Filing DateMonday, May 24, 2021
Status692 - WITHDRAWN BEFORE PUBLICATION
Status DateTuesday, January 11, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; monoclonal antibodies

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, August 19, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Trademark Events


Event DateEvent Description
Monday, December 27, 2021EXAMINER'S AMENDMENT ENTERED
Thursday, May 27, 2021NEW APPLICATION ENTERED
Thursday, August 19, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, December 27, 2021ASSIGNED TO EXAMINER
Monday, December 27, 2021EXAMINERS AMENDMENT -WRITTEN
Monday, December 27, 2021EXAMINERS AMENDMENT E-MAILED
Monday, December 27, 2021NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, December 28, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 29, 2021ASSIGNED TO LIE
Tuesday, January 11, 2022WITHDRAWN FROM PUB - OG REVIEW QUERY
Thursday, June 23, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, August 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, August 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sunday, December 8, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Sunday, December 8, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Sunday, December 8, 2024ASSIGNED TO LIE